Kolexia
Deville Jean-Laurent Oncologie médicale
Deville Jean-Laurent
Oncologie médicale
Hôpital La Timone
Marseille, France
84 Activités
8 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Tumeurs du rein Tumeurs osseuses Carcinome transitionnel Tumeurs de la vessie urinaire Métastase tumorale

Collaborateurs

Voir plus
Lechevallier Eric
Lechevallier Eric
Hôpital La Conception, Marseille, France
Pignot Geraldine
Pignot Geraldine
Centre Paoli-Calmettes, Marseille, France
Dupuis Charlotte
Dupuis Charlotte
Hôpital La Timone, Marseille, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Janssen
8 collaboration(s)
Dernière en 2021
MSD
4 collaboration(s)
Dernière en 2021
BMS
3 collaboration(s)
Dernière en 2022
Parexel
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
Un cas de dermite de rappel sous immunothérapie anti-PDL1
Journées dermatologiques de Paris 2023   01 décembre 2023
IREKI: Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer
Essai Clinique (Institut du Cancer de Montpellier)   19 octobre 2023
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Essai Clinique (Unicancer)   29 août 2023
GETUG-StORM-01: A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Essai Clinique (Centre François-Baclesse)   31 juillet 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Journal for immunotherapy of cancer   29 mai 2023
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.
Frontiers in oncology   19 janvier 2023
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Cell reports. Medicine   21 octobre 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
Cancer chemotherapy and pharmacology   11 février 2022
Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients.
Cancers   30 décembre 2021